RALA
Ras-related protein Ral-A
Also known as: RAL, RALA_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P11233
- Gene
- RALA
- Ensembl
- ENSG00000006451
- Chromosome
- 7
- Canonical length
- 206 aa
- Protein class
- Disease related genes, Enzymes, Human disease related genes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins
- Subcellular location
- Plasma membrane,Focal adhesion sites
OverviewNCBI Gene
The product of this gene belongs to the small GTPase superfamily, Ras family of proteins. GTP-binding proteins mediate the transmembrane signaling initiated by the occupancy of certain cell surface receptors. This gene encodes a low molecular mass ras-like GTP-binding protein that shares about 50% similarity with other ras proteins. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
206 residues, UniProt reviewed canonical sequence.
>P11233|RALA
1 MAANKPKGQN SLALHKVIMV GSGGVGKSAL TLQFMYDEFV EDYEPTKADS YRKKVVLDGE
61 EVQIDILDTA GQEDYAAIRD NYFRSGEGFL CVFSITEMES FAATADFREQ ILRVKEDENV
121 PFLLVGNKSD LEDKRQVSVE EAKNRAEQWN VNYVETSAKT RANVDKVFFD LMREIRARKM
181 EDSKEKNGKK KRKSLAKRIR ERCCILLocalizationUniProt · AlphaFold · HPA
Whether an antibody against RALA can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.31
- Highest tissue expression
- 51 nTPM
Expression across tissuesHPA
Tissue
- esophagus: 51 nTPM
- spinal cord: 41 nTPM
- lung: 39 nTPM
- tonsil: 33 nTPM
- stomach: 32 nTPM
- duodenum: 31 nTPM
Single-cell type
- esophageal apical cells: 1,858 nCPM
- esophageal suprabasal cells: 533 nCPM
- endometrial glandular cells: 462 nCPM
- endometrial secretory cells: 445 nCPM
- cdc: 330 nCPM
- suprabasal keratinocytes: 289 nCPM
Immune cell
- basophil: 38 nTPM
- T-reg: 28 nTPM
- naive CD4 T-cell: 26 nTPM
- NK-cell: 23 nTPM
- naive CD8 T-cell: 23 nTPM
- myeloid DC: 23 nTPM
Brain region
- white matter: 43 nTPM
- spinal cord: 40 nTPM
- medulla oblongata: 38 nTPM
- midbrain: 36 nTPM
- cerebellum: 35 nTPM
- thalamus: 34 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about RALA.
Disease | AllUniProt
Conditions RALA is implicated in, by any mechanism.
- Hiatt-Neu-Cooper neurodevelopmental syndrome (HINCONS) MIM:619311
Disease | GeneticClinVar
14 pathogenic / likely-pathogenic of 127 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Hiatt-Neu-Cooper neurodevelopmental syndrome
- Inborn genetic diseases
- Intellectual disability
- Neurodevelopmental delay
ReferencesPubMed · IEDB
Publications for RALA from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
6 publications
- Prevalence of autoantibodies against Ras-like GTPases, RalA, in patients with gastric cancer.
2020 · Mol Clin Oncol · RCR 0.6 · 11 citations - Presence of serum RalA and serum p53 autoantibodies in 1833 patients with various types of cancers.
2022 · Int J Clin Oncol · RCR 0.5 · 6 citations - Possible predictive significance of serum RalA autoantibodies on relapse-free survival in patients with colorectal cancer.
2021 · Mol Clin Oncol · RCR 0.4 · 5 citations - Immunogenicity of Ra1A and its tissue-specific expression in hepatocellular carcinoma.
2009 · Int J Immunopathol Pharmacol · RCR 0.3 · 13 citations - Evaluation and characterization of anti-RalA autoantibody as a potential serum biomarker in human prostate cancer.
2016 · Oncotarget · RCR 0.2 · 7 citations
Show 1 more
- Novel combined tumor autoantibody detection in serological diagnosis of gastric cancer.
2025 · Int J Clin Exp Pathol
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.27
- gnomAD pLI
- 0.97
- gnomAD missense Z
- 2.7
- DepMap mean gene effect
- -0.13
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 10% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cell division
- chemotaxis
- establishment of protein localization to mitochondrion
- exocytosis
- neural tube closure
- positive regulation of epidermal growth factor receptor signaling pathway
- positive regulation of filopodium assembly
- positive regulation of mitochondrial fission
- Ras protein signal transduction
- receptor internalization
- regulation of actin cytoskeleton organization
- regulation of exocytosis
- regulation of postsynaptic neurotransmitter receptor internalization
- signal transduction
- membrane raft localization
Molecular functions
- ATPase binding
- Edg-2 lysophosphatidic acid receptor binding
- G protein activity
- GDP binding
- GTP binding
- GTPase activity
- myosin binding
- ubiquitin protein ligase binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of RALA in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads RALA as an antibody target. Whether an autoantibody or antibody against RALA could matter depends on whether native RALA is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
RALA is annotated at the cell surface, where native RALA is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label RALA as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...